BioKier
BioKier, a US-based pharmaceutical firm, innovates drugs for diabetes and related disorders.
Founded
2008BioKier, a US-based pharmaceutical firm, innovates drugs for diabetes and related disorders.
BioKier, founded in Chapel Hill, United States, is an early-stage pharmaceutical company focused on developing innovative drugs for diabetes and related disorders. The company's core mission is to improve the quality of life for individuals with diabetes through groundbreaking therapeutic solutions. BioKier's primary product, BKR-017, is designed to address type 2 diabetes, with ongoing clinical studies demonstrating its potential efficacy. The firm aims to revolutionize diabetes treatment and expand its market reach within the pharmaceutical industry.
Notable figures associated with BioKier include a team of experienced management and advisors who bring extensive expertise in pharmaceutical development and diabetes research. The company has achieved significant milestones, including the completion of a 12-week clinical study and a 4-week study of BKR-017 in type 2 diabetes patients, showcasing promising results. BioKier's innovative approach and successful clinical trials underscore its potential impact on diabetes treatment, positioning it as a key player in the healthcare sector.
Companies similar to BioKier include EIR Pharmaceuticals, Kira Pharmaceuticals, Tabomedex and Kiniksa Pharmaceuticals.
BioKier was founded in 2008.
BioKier's headquarters is located in Chapel Hill, NC, US.
BioKier's most recent funding round was for $150k (USD) in January 2015.
As of Jan 1, 2015, BioKier has disclosed funding of $2.9M (USD). Undisclosed round amounts are excluded.
BioKier has 5 employees as of Feb 5, 2024.
Kiniksa Pharmaceuticals
kiniksa.com
